Polypills boost adherence
May 6, 2014
BOTH patient adherence and
risk factor control are enhanced
when patients at high risk of heart
attack or stroke receive a polypill,
compared to usual care, according
to new data presented for the first
time this week at the World Heart
Federation’s World Congress of
Cardiology 2014.
WCC 2014 is taking place in
Melbourne from 04 to 07 May.
The ‘Single Pill to Avert
Cardiovascular Events’ (SPACE)
project, led by researchers from
The George Institute for Global
Health, analysed data from
3,140 patients with established
cardiovascular disease (CVD) or at
high risk of CVD from Europe, India
and Australasia.
“These results are an important
step forward in the polypill journey
and management of cardiovascular
disease”, commented Ruth Webster
of the George Institute for Global
Health, Sydney.
“Most patients globally either
don’t start or don’t continue taking
all the medications they need,
which can lead to untimely death
or further CVD events.”
The Heart Foundation of Australia
and World Heart Federation state
that CVD is the number one cause
of death globally, killing 17.3m
people each year.
To read more, CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 06 May 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 May 14
